- Home
- SNDX vs NFJ Comparison
SNDX vs NFJ Comparison
Compare SNDX & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- NFJ
- Stock Information
- Founded
- SNDX 2005
- NFJ 2005
- Country
- SNDX United States
- NFJ United States
- Employees
- SNDX N/A
- NFJ N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- NFJ Finance: Consumer Services
- Sector
- SNDX Health Care
- NFJ Finance
- Exchange
- SNDX Nasdaq
- NFJ Nasdaq
- Market Cap
- SNDX 1.1B
- NFJ 1.2B
- IPO Year
- SNDX 2016
- NFJ N/A
- Fundamental
- Price
- SNDX $15.71
- NFJ $12.88
- Analyst Decision
- SNDX Strong Buy
- NFJ
- Analyst Count
- SNDX 10
- NFJ 0
- Target Price
- SNDX $38.40
- NFJ N/A
- AVG Volume (30 Days)
- SNDX 2.2M
- NFJ 223.5K
- Earning Date
- SNDX 11-04-2025
- NFJ 01-01-0001
- Dividend Yield
- SNDX N/A
- NFJ 9.01%
- EPS Growth
- SNDX N/A
- NFJ N/A
- EPS
- SNDX N/A
- NFJ N/A
- Revenue
- SNDX $77,933,000.00
- NFJ N/A
- Revenue This Year
- SNDX $585.73
- NFJ N/A
- Revenue Next Year
- SNDX $94.17
- NFJ N/A
- P/E Ratio
- SNDX N/A
- NFJ N/A
- Revenue Growth
- SNDX 2126.66
- NFJ N/A
- 52 Week Low
- SNDX $8.58
- NFJ $10.45
- 52 Week High
- SNDX $22.50
- NFJ $12.86
- Technical
- Relative Strength Index (RSI)
- SNDX 58.19
- NFJ 48.85
- Support Level
- SNDX $15.59
- NFJ $12.95
- Resistance Level
- SNDX $16.65
- NFJ $13.25
- Average True Range (ATR)
- SNDX 0.81
- NFJ 0.12
- MACD
- SNDX -0.23
- NFJ -0.01
- Stochastic Oscillator
- SNDX 28.68
- NFJ 9.76
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.